If You Invested in Immunome Inc (IMNM)

Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage biotechnology company focused on targeted oncology. According to the company’s public disclosures, Immunome is committed to developing first-in-class and best-in-class targeted cancer therapies. The company is advancing a portfolio of investigational therapeutics that includes small molecules, antibody-drug conjugates (ADCs) and radiotherapy candidates aimed at improving outcomes for patients with solid tumors and hematologic malignancies.

Business focus and therapeutic approach

Immunome describes itself as a clinical-stage targeted oncology company. Its strategy centers on developing targeted therapies that address specific molecular drivers of cancer. The company highlights leadership experience in the design, development and commercialization of targeted cancer therapies, including ADC therapies. This background informs Immunome’s emphasis on precision approaches such as gamma secretase inhibition, ROR1-targeted ADCs, and FAP-targeted radioligands.

The company’s disclosures emphasize a focus on first-in-class and best-in-class assets. In practice, this means pursuing targets and payload technologies that are intended to differentiate from existing treatments, including efforts to address resistance mechanisms and tumor heterogeneity that can limit the effectiveness of other therapies.

Key pipeline programs

Immunome’s publicly described pipeline includes several named product candidates at different stages of development:

• Varegacestat (formerly AL102) – an investigational, oral, once-daily gamma secretase inhibitor (GSI). Varegacestat is in late-stage clinical development for patients with progressing desmoid tumors. The company reported positive topline results from the global pivotal Phase 3 RINGSIDE trial, in which varegacestat met the primary endpoint of improving progression-free survival versus placebo and met all key secondary endpoints. Based on these data, Immunome has stated plans to submit a New Drug Application (NDA) for varegacestat to the U.S. Food and Drug Administration.
• IM-1021 – a ROR1-targeted ADC that is in a Phase 1 clinical trial. Company updates note objective responses observed in B-cell lymphoma patients at multiple dose levels, and IM-1021 incorporates Immunome’s proprietary HC74 TOP1 inhibitor payload.
• IM-3050 – a FAP-targeted radiotherapy / radioligand candidate that has received Investigational New Drug (IND) clearance. Immunome has indicated plans to initiate a Phase 1 study following delivery of third-party diagnostic radiotracer supply.
• Preclinical ADC programs – IM-1617, IM-1335 and IM-1340 are described as preclinical ADCs pursuing undisclosed solid tumor targets. These programs incorporate the HC74 payload and are being advanced toward potential IND submissions.

HC74 TOP1 inhibitor ADC payload

A notable element of Immunome’s platform is HC74, the company’s proprietary topoisomerase I (TOP1) inhibitor payload used in its ADC programs. According to Immunome’s SEC filings, HC74 was intentionally designed to address limitations seen with existing TOP1 inhibitor payloads such as deruxtecan (DXd). The company reports that HC74 has demonstrated:

• Lower efflux potential in preclinical studies, intended to overcome payload resistance mediated by efflux transporters such as P-glycoprotein (P-gp) and multidrug resistance associated protein 1 (MRP1).
• Higher membrane permeability, which is intended to enhance bystander activity by enabling payload to affect neighboring tumor cells that may not express the ADC target.
• Superior cytotoxic activity across a broad panel of cell lines compared with DXd in preclinical testing.

Immunome’s disclosures describe preclinical data in models of colorectal cancer and other tumors suggesting that HC74 ADCs may retain activity in settings where other TOP1 inhibitor therapies show resistance, and may provide stronger bystander effects in tumors with heterogeneous target expression.

Clinical development in desmoid tumors

Varegacestat is being developed for desmoid tumors, which are aggressive, non-metastatic soft tissue tumors that can cause significant pain, deformity and organ damage. In the Phase 3 RINGSIDE trial, Immunome reports that varegacestat:

• Achieved a statistically significant and clinically meaningful improvement in progression-free survival versus placebo.
• Delivered a confirmed objective response rate substantially higher than placebo, based on blinded independent central review using RECIST v1.1.
• Showed substantial reductions in tumor volume and improvements in pain-related endpoints.

The company also notes that varegacestat was generally well tolerated with a safety profile consistent with the GSI class, while also reporting specific adverse events and ovarian toxicity in premenopausal women in its SEC filings. Immunome has indicated plans to share additional RINGSIDE data at a major medical conference and to pursue regulatory review.

Broader oncology pipeline and strategy

Beyond desmoid tumors, Immunome’s pipeline reflects a broader focus on solid tumors and hematologic cancers. IM-1021 targets ROR1, a receptor expressed in certain B-cell malignancies and solid tumors, and early clinical data have shown objective responses in B-cell lymphoma patients at multiple dose levels. IM-3050 targets fibroblast activation protein (FAP), which is associated with tumor stroma, through a radioligand approach. The company also references additional early-stage ADCs directed at undisclosed solid tumor targets.

Immunome’s public materials frequently highlight leadership experience in ADC development and targeted cancer therapeutics. The company positions its programs as part of an emerging pipeline of targeted oncology therapies that, in its view, have potential to meaningfully improve patient outcomes if successfully developed and approved.

Capital markets and listing

Immunome’s common stock trades on The Nasdaq Capital Market under the ticker symbol IMNM. The company has used public equity offerings to support its development programs, including an underwritten public offering of common stock pursuant to an effective shelf registration statement on Form S-3 and a follow-on offering described in its Form 8-K filings. Immunome has also reported the use of inducement equity awards under a 2024 Inducement Plan in connection with hiring new employees, consistent with Nasdaq Listing Rule 5635(c)(4).

Headquarters and sector classification

SEC filings list Immunome’s principal offices in Bothell, Washington. The company is classified in the Pharmaceutical Preparation Manufacturing industry within the broader Manufacturing sector. Its activities, however, are described as those of a clinical-stage biotechnology and targeted oncology company, reflecting its focus on research and development rather than commercial manufacturing.

Position within the biotechnology landscape

Within the biotechnology and oncology space, Immunome’s disclosures emphasize three main pillars: late-stage development of varegacestat for desmoid tumors, early clinical development of the ROR1-targeted ADC IM-1021, and a growing ADC platform built around the HC74 payload. The company’s filings and press releases underscore the importance of addressing resistance mechanisms, improving bystander activity, and targeting tumor-specific antigens and microenvironment components such as FAP.

Investors and researchers reviewing IMNM stock and Immunome’s business can use these publicly available descriptions to understand the company’s focus on targeted oncology, its lead clinical programs, and its ADC payload technology. As with any clinical-stage biotechnology company, the outcome of ongoing and future clinical trials, as well as regulatory review processes, will be central to the eventual commercial impact of these programs.

Frequently asked questions about Immunome (IMNM)